Equities

Kelyniam Global Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KLYG:PKC

Kelyniam Global Inc

Actions
  • Price (USD)0.1398
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change-54.93%
  • Beta0.4338
Data delayed at least 15 minutes, as of Feb 09 2026 17:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company specializing in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient’s computed tomography (CT) data, its 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours. It distributes its products throughout the United States via independent distributors and sales representatives.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2005
  • Employees0.00
  • Location
    Kelyniam Global Inc97 River RoadCANTON 06019United StatesUSA
  • Phone+1 (800) 280-8192
  • Fax+1 (501) 641-2000
  • Websitehttps://kelyniam.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Co-Diagnostics Inc507.90k-32.18m5.05m132.00--0.1003--9.95-29.44-29.440.455124.820.00870.28444.343,847.73-54.95-1.67-59.80-1.7834.0382.14-6,336.17-3.713.51--0.00---42.5378.68-6.53--45.89--
Dalrada Financial Corp18.37m-23.89m5.29m0.00------0.2878-0.2172-0.21720.1626-0.13030.90894.865.34---118.42-100.15-1,575.08-1,511.4525.5728.94-130.29-92.980.2685-6.36----2.3276.7114.86--15.56--
ADM Tronics Unlimited Inc3.36m-129.58k6.02m7.00--6.8317.111.79-0.0019-0.00190.04970.0131.474.956.60---5.67-17.71-10.33-27.7539.0740.78-3.86-19.080.8633-3.740.3461--7.81-1.7285.97------
Innovative Eyewear Inc2.39m-7.85m6.05m11.00--0.5739--2.53-2.63-2.630.73691.970.21011.4529.13217,504.50-68.92-143.06-73.91-176.8022.844.06-327.98-574.8910.13--0.00--41.99220.75-16.55------
Biomerica Inc4.46m-4.03m6.92m53.00--1.52--1.55-1.64-1.641.761.500.672.543.9284,113.21-60.49-51.40-81.87-60.825.6111.63-90.29-71.362.29--0.00---1.92-4.5216.81---20.83--
iTonic Holdings Ltd305.22k-2.41m7.04m10.00--1.49--23.07-0.1637-0.16370.02150.27750.09430.62922.0230,522.00-74.52---100.07--82.86---790.56--11.36--0.0287---28.70---173.85------
Kelyniam Global Inc-100.00bn-100.00bn7.07m0.00--9.59----------0.0146------------------------0.6993--0.3831--------------
Scientific Industries Inc8.95m-1.24m7.16m67.00--0.5743--0.7994-0.1394-0.13890.80271.040.64261.538.80133,628.40-8.91---10.06--41.46---13.87--6.34--0.00---3.59--29.09------
Dror Ortho-Design Inc0.00-3.12m7.18m3.00---------0.0033-0.00330.00-0.00240.00----0.00-405.89-214.68---759.55-------276,220.70---69.87---------61.89------
Biotricity Inc15.08m-4.87m7.52m46.00------0.4987-0.1887-0.18870.5821-1.172.601.498.38327,858.70-77.97-229.45----79.8464.92-30.02-184.400.1389-0.1077----14.3257.6120.01------
Tenon Medical Inc3.23m-12.81m8.00m27.00--3.69--2.47-2.76-2.760.57250.55760.27631.562.96119,740.70-109.47-174.04-149.09-976.4552.4034.39-396.26-788.171.70--0.00--11.92127.6112.25------
Meihua International Medical Tech Co Ltd89.55m9.27m8.35m619.000.28520.01870.84950.093234.1234.12302.14520.790.484453.651.05144,664.905.029.695.9011.6934.3137.0210.3513.995.6689.960.06490.00-0.19494.01-6.73-6.81-56.87--
ALR Technologies SG Ltd9.49k-8.00m8.39m6.00------884.20-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Nexalin Technology Inc156.94k-8.68m8.44m6.00--1.73--53.79-0.6345-0.63450.01090.26220.03020.300413.5926,156.67-167.17-166.16-178.46-334.5469.5176.06-5,530.09-1,178.9513.03--0.00--52.34-4.04-63.64------
SeaStar Medical Holding Corp881.00k-13.67m8.65m19.00--0.7138--9.82-16.43-16.430.68743.360.0876--6.1046,368.42-135.86---290.37--95.35---1,551.08--3.64--0.00------5.34------
AccuStem Sciences Inc0.00-1.61m8.95m2.00---------0.1163-0.11630.00-0.18110.00----0.00-192.46--------------------------26.60------
Data as of Feb 09 2026. Currency figures normalised to Kelyniam Global Inc's reporting currency: US Dollar USD

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
Miller Wealth Advisors LLCas of 31 Dec 20256.00k0.05%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.